Global First published in the November 2025 issue of DIA’s Global Forum, this article by Victoria Gamermanusa (RWD Insights) tackles one of rare disease research’s toughest dilemmas: how to run credible efficacy trials when patient numbers make traditional statistics unworkable. She charts how AI, Bayesian methods, transfer learning, and synthetic data…

USA The latest updates from the US healthcare and life sciences scene. Eli Lilly partners with Nvidia to build a supercomputer for faster drug discovery; Trump secures “most-favored-nation” pricing deals with AstraZeneca and EMD Serono; former FDA vaccine chief Peter Marks joins Lilly to head infectious diseases; Organon CEO Kevin Ali…

Global Pharma executives are used to navigating complexity, but few periods have tested their judgement like the present. As Brendan Shaw writes, between Washington’s renewed push for “most favoured nation” (MFN) drug pricing, fresh waves of US tariffs, and a volatile global policy mood, the rules of engagement for global pharma…

USA In 2025, just 318 US biotech deals closed in Q2 – the lowest in a decade – even as mega-rounds propped up total investment volumes. For a sector that was booming during the pandemic era, the contrast could not be starker. Leaders from trade organisations and innovation accelerators agree on…

Global In a pharma industry increasingly squeezed by falling legacy revenues, political pricing crackdowns, and the need to deliver the next wave of science at speed and scale, the right leadership is crucial. Four of the Top 25 global pharma companies – Novo Nordisk (ranked 10th), GSK (12th), Takeda (14th), and…

Global First published in ISPOR’s Value & Outcomes Spotlight magazine, Shirley V. Wang, PhD, MSc of Brigham and Women’s Hospital, Harvard Medical School, argues that there is an urgent need for transparency in health economics and outcomes research (HEOR). Wang posits that the growing reliance on real-world evidence (RWE) in healthcare…

USA The latest stories from healthcare and the life sciences in the US. RFK Jr shares his 128 recommendations for addressing childhood chronic disease; Suspension of Capsida’s gene therapy clinical trial after patient death; Courts half another attempt to challenge the IRA’s negation program; Takeda scoops up former Lilly exec to…

USA The latest stories from healthcare and the life sciences in the US. Vinay Prasad is reinstated as head of the FDA’s CBER following a brief resignation; HHS fires Gray Delany amid fallout from abrupt mRNA contract cuts; the federal Task Force on Safer Childhood Vaccines is revived after three decades…

USA The latest stories from healthcare and the life sciences in the US. The FDA names Stanford’s George Tidmarsh as the new head of CDER; AstraZeneca commits USD 50 billion to new US manufacturing and R&D projects; Moderna cancels its planned mRNA facility in Japan; Sarepta refuses to halt Elevidys shipments…

Global Alzheimer’s Disease takes a heavy toll; not just on patients and caregivers, but on society as a whole. As populations age, this complex and often-stigmatised condition is becoming harder to ignore. Despite recent breakthroughs, we are still far from having the right tools: better diagnostics, effective treatments, and smarter healthcare…

USA Having terminated dozens of HIV-related research grants, the Trump administration’s assault on the field continues. In a major blow to the decades-long search for a vaccine, the US federal government has pulled the plug on the HIV vaccine programme run by the US National Institute of Health (NIH) –the world’s…

Global Writing in ISPOR’s Value and Outcomes Spotlight magazine, Beth Fand Incollingo looks at why health economics and outcomes research may hold the key to solving some of healthcare’s most entrenched access and affordability issues.   Healthcare can only be widely effective if most patients can access and afford it. Yet,…